Observational studyBMC cancer2025
Duration of hepatic portal occlusion is a valuable predictor for postoperative nausea and vomiting in patients underwent liver resection for liver cancer.
Observational study in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05894408 (Portal Vein Occlusion is a Valuable Predictor for Postoperative Nausea and Vomiting in Patients With Liver Cancer), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Portal Vein Occlusion is a Valuable Predictor for Postoperative Nausea and Vomiting in Patients With Liver Cancer: A Prospective Cohort Study
Who cites it
2 citing papers in PubMed.
- Construction and Validation of a Risk Prediction Model for Postoperative Nausea and Vomiting in Patients with Liver Cancer.Journal of hepatocellular carcinoma · 2026Article
- Opioid type, rather than liver function, is associated with postoperative nausea and vomiting after painless gastroscopy in decompensated cirrhosis.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPostoperative nausea and vomiting (PONV) is one of the most frequent complications after surgery. PONV prophylaxis has been strongly recommended, and identifying risk factors is the first step. The well-known PONV risk assessment tools were not validated in the liver cancer population, however, no study has explored the relationship between PONV and liver surgery-specific factors. This study aimed to identify whether there was an association between hepatic portal occlusion and PONV among patients after hepatectomy.
methodsParticipants were consecutively enrolled during June 2023 to August 2023 in the cancer center in Fudan Univesity Zhongshan Hospital. Liver cancer patients who underwent liver resection surgery were eligible. The impact of hepatic portal occlusion on PONV was determined using Logistic regression models.
resultsA total of 380 patients were consecutively included in the study, and 192 patients (50.53%) developed PONV. A linear relationship between PONV and the time of hepatic portal occlusion was observed. Even adjusted for 9 PONV-related factors, the hepatic portal occlusion was still significantly correlated with PONV (OR = 1.22, 95%CI = 1.05-1.43, P = 0.012). In addition, the numbers of hepatic portal occlusion were positively related to the incidence of PONV (OR = 1.30, 95% CI = 1.04-1.62, P for trend = 0.022); as the number of occlusions increased, patients were more likely to experience PONV.
conclusionsHepatic portal occlusion was an important PONV predictor for patients undergoing liver surgery and should be used to update PONV scoring systems to guide personalized prophylactic antiemetics use in clinical practice.
trial registrationThe study was registered with the US National Institutes of Health ClinicalTrials.gov (NCT05894408) on May 30, 2023.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.